Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lipton

Showing results (91-100 of 148) with videos related to

Pageof 15
Sort By:
The Oncologist|August 19, 2016
N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal MetastasesArlindo R Ferreira, Irina Alho, Ning Shan, et al.
Cancer|April 5, 2007
Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancerAllan Lipton, Suhail M Ali, Kim Leitzel, et al.
The Oncologist|April 24, 2012
Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administrationAlfredo Berruti, Richard Cook, Fred Saad, et al.
Cancer|April 2, 2011
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapyAllan Lipton, Kim Leitzel, Suhail M Ali, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activityVera Hirsh, Pierre P Major, Allan Lipton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancerJean-Jacques Body, Thierry Facon, Robert E Coleman, et al.
Clinical Chemistry|July 27, 2002
Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancerSuhail M Ali, Kim Leitzel, Vernon M Chinchilli, et al.
Cancer|July 28, 2010
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumabAllan Lipton, Wolfgang J Köstler, Kim Leitzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonatesKarim Fizazi, Allan Lipton, Xavier Mariette, et al.
Clinical Breast Cancer|December 15, 2010
Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancerKathy S Albain, Lisa Carey, William J Gradishar, et al.
Pageof 15

Showing results (91-100 of 148) with videos related to

Sort By:
Pageof 15
The Oncologist|August 19, 2016
N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal MetastasesArlindo R Ferreira, Irina Alho, Ning Shan, et al.
Cancer|April 5, 2007
Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancerAllan Lipton, Suhail M Ali, Kim Leitzel, et al.
The Oncologist|April 24, 2012
Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administrationAlfredo Berruti, Richard Cook, Fred Saad, et al.
Cancer|April 2, 2011
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapyAllan Lipton, Kim Leitzel, Suhail M Ali, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activityVera Hirsh, Pierre P Major, Allan Lipton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancerJean-Jacques Body, Thierry Facon, Robert E Coleman, et al.
Clinical Chemistry|July 27, 2002
Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancerSuhail M Ali, Kim Leitzel, Vernon M Chinchilli, et al.
Cancer|July 28, 2010
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumabAllan Lipton, Wolfgang J Köstler, Kim Leitzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonatesKarim Fizazi, Allan Lipton, Xavier Mariette, et al.
Clinical Breast Cancer|December 15, 2010
Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancerKathy S Albain, Lisa Carey, William J Gradishar, et al.
Pageof 15